MP Biomedicals Receives CE Mark for New Patented Multiparameter Hepatitis C Test
MP Biomedicals announced it has received CE Marking (Conformite Europeenne) in the European Union for its innovative multiparameter patented Hepatitis C test - MULTISURE HCV antibody test.
July 2, 2013 (Newswire.com) - MP Biomedicals announced it has received CE Marking (Conformite Europeenne) in the European Union to market its innovative multiparameter patented Hepatitis C test - MULTISURE HCV antibody test. This test is intended to fill the gap that exists in the current Hepatitis C diagnosis and may provide additional information about the infection profile. MP Diagnostics MULTISURE HCV is a qualitative multiparameter immunochromatographic assay, intended for the detection and differentiation of Hepatitis C antibodies that may be present in patients with acute or chronic Hepatitis C infection. This innovative test is developed based on the patented reverse-flow technology, giving greater sensitivity and stronger visual signals.
MP Diagnostics MULTISURE HCV Antibody Assay is a multiparameter platform test that uses human whole blood, plasma or serum. Test has a short test-time and can detect & differentiate HCV antibodies against both structural and non-structural proteins across all six genotypes. MULTISURE HCV Antibody Assay is instrument free, easy to use and is suitable for use as Point-of-care or with automation and does not require highly trained personnel to perform the test. The test has excellent correlation with PCR, EIA & Immunoblot.
"With our Multiparameter Patented MULTISURE HCV Antibody Assay, medical fraternity can get additional information about the infection profile as well as stage; patients may be able to receive earlier diagnosis, timely treatment and thereby a better disease management." commented Milan Panic, Chairman and CEO of MP Biomedicals
About Hepatitis C
It has been estimated that 3 to 4 million people are infected with HCV each year. People with chronically infected HCV are at risk of developing liver cirrhosis and/or liver cancer. More than 350,000 people die each year from HCV-related liver disease. Hepatitis C is the leading cause of liver transplantation and no vaccine against Hepatitis C is available. Though with earlier detection and diagnosis, patients have a hope of getting timely treatment and care to manage the condition better.
About MP Biomedicals LLC
MP Biomedicals is a world-wide corporation, with ISO-certified and FDA-approved manufacturing and distribution facilities throughout the globe and headquartered in Southern California, USA. MP Biomedicals manufactures and sells more than 55,000 products and is one of the only companies in the industry to offer a comprehensive line of life science, fine chemical and diagnostic products. MP Biomedicals is marketing their high quality diagnostics products in Western Blot, ELISA and Rapid Tests along with the analyzer solutions with a rich tradition of 25 years. A vast network of global distributors, satellite facilities and offices throughout Europe, Asia Pacific and the Americas assures customers top quality products delivered whenever and wherever needed. For more information, please visit www.mpbio.com
Director - Global Marketing Communication
Product/ Sales enquiries:
email@example.com (Asia Pacific)
firstname.lastname@example.org (North America)
email@example.com (Latin America)
Categories: Infectious Diseases